) [153]. This Process is currently not scalable because it relies on highly-priced startup substrates which can be applied to produce psilocybin in less costly chemical synthesis methodologies. A methodology for de novo creation of psilocybin and tryptamine derivatives in Saccharomyces cerevisiae, Ideal dosing for psilocybin pharmacotherapy: Considering body weight-adjusted waiting for link from Forum Profiles